155 related articles for article (PubMed ID: 36675237)
1. Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent.
Malacrida A; Deschamps-Wright M; Rigolio R; Cavaletti G; Miloso M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675237
[TBL] [Abstract][Full Text] [Related]
2. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
3. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
4. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
5. Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.
Malacrida A; Cavaletti G; Miloso M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008638
[TBL] [Abstract][Full Text] [Related]
6. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
8. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR
Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
[TBL] [Abstract][Full Text] [Related]
13. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Gaelzer MM; Coelho BP; de Quadros AH; Hoppe JB; Terra SR; Guerra MC; Usach V; Guma FC; Gonçalves CA; Setton-Avruj P; Battastini AM; Salbego CG
PLoS One; 2016; 11(4):e0154612. PubMed ID: 27123999
[TBL] [Abstract][Full Text] [Related]
15. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
16. P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549.
Zhang C; Zhu H; Yang X; Lou J; Zhu D; Lu W; He Q; Yang B
J Cancer Res Clin Oncol; 2010 Mar; 136(3):437-45. PubMed ID: 19727814
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A
Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.
Park EY; Woo Y; Kim SJ; Kim DH; Lee EK; De U; Kim KS; Lee J; Jung JH; Ha KT; Choi WS; Kim IS; Lee BM; Yoon S; Moon HR; Kim HS
Int J Biol Sci; 2016; 12(12):1555-1567. PubMed ID: 27994519
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model.
Luta G; Butura M; Tiron A; Tiron CE
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]